BBIO BridgeBio Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—
Margins
Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%
Returns
ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $502.08M | $221.90M |
| Cost of revenue | $20.96M | $3.88M |
| Gross profit | $481.11M | $218.02M |
| R&D expense | $451.95M | $506.46M |
| SG&A expense | $531.23M | $288.93M |
| Operating income | -$523.41M | -$592.97M |
| Interest expense | $53.10M | $90.99M |
| Pretax income | -$732.50M | -$542.19M |
| Income tax | $435,000 | $1.15M |
| Net income | -$724.93M | -$535.76M |
| EBITDA | -$517.98M | -$586.90M |
| EPS (basic) | -3.78 | -2.88 |
| EPS (diluted) | -3.78 | -2.88 |
| Weighted avg. shares (diluted) | 191.53M | 186.08M |
| Balance sheet | ||
| Cash & equivalents | $570.12M | $681.10M |
| Short-term investments | $17.36M | $0 |
| Receivables | $139.44M | $4.72M |
| Inventory | $26.75M | $0 |
| Current assets | $797.75M | $720.69M |
| PP&E, net | $5.37M | $7.01M |
| Intangibles | $28.08M | $23.93M |
| Total assets | $936.02M | $919.34M |
| Current liabilities | $287.97M | $154.40M |
| Long-term debt | $2.01B | $437.34M |
| Total debt | $2.01B | $437.34M |
| Total liabilities | $3.01B | $2.38B |
| Shareholders' equity | -$2.09B | -$1.47B |
| Net debt | $1.44B | -$243.76M |
| Shares outstanding | 194.77M | 190.04M |
| Cash flow statement | ||
| Operating cash flow | -$445.91M | -$520.73M |
| Capital expenditure | $1.10M | $933,000 |
| Free cash flow | -$447.01M | -$521.66M |
| Investing cash flow | -$24.49M | $60.78M |
| Financing cash flow | $359.29M | $748.46M |
| Depreciation & amortization | $5.43M | $6.08M |
| Stock-based compensation | $133.02M | $95.80M |
| Share buybacks | $48.28M | $0 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.